Abcentra’s Orticumab Targets Chronic inflammation
Wednesday October 16, 2019
Chronic inflammation can be a primary contributor to many fatal and life-threatening diseases such as cancers, rheumatoid arthritis, atherosclerosis, and other cardiovascular diseases. While inflammation tends to have a negative connotation, inflammation occurs in the body as a defense mechanism or self-protection as a way to begin the healing process when the immune system recognizes damaged cells, irritants, and pathogens. Chronic inflammation, however, often begins with a cellular response, but morphs into a lingering state that persists for months or years when the immune system’s response fails to eliminate the problem. While inflammation is a naturally occurring bodily process, chronic inflammation can eventually cause several diseases and conditions that can lead to a lower quality of life for patients.
The World Health Organization (WHO) ranks chronic diseases as the greatest threat to human health. The prevalence of diseases associated with chronic inflammation is anticipated to increase persistently for the next 30 years in the United States. In 2000, nearly 125 million Americans were living with chronic conditions and 61 million (21 percent) had more than one. Worldwide, 3 out of 5 people die due to chronic inflammatory diseases such as stroke, chronic respiratory diseases, heart disorders, cancer, obesity, and diabetes.
Therapies that target and treat inflammation are an important tool in the fight against inflammatory diseases like psoriasis and rheumatoid disease. However, traditional medicines are limited in reach and may have severe side effects that put patients at unnecessary risk.
It’s time to create another option. Abcentra’s lead candidate, orticumab, is being developed to treat diseases where chronic inflammation is implicated, like plaque psoriasis and accelerated atherosclerosis in patients with rheumatoid disease. Orticumab is the first and only fully-human monoclonal antibody of its kind targeting oxLDL – oxidized low-density lipoprotein. By targeting oxLDL specifically, Abcentra hopes to alleviate symptoms and treat underlying disease, creating a fuller life for patients.
Abcentra aims to bring new, safer and more effective treatment options to patients with inflammatory diseases. For more information about Abcentra and our lead candidate, orticumab, visit our website and be sure to check out our blogs.